4DMedical Limited
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- 4DMedical Limited is an Australian-based global medical technology company specializing in advanced respiratory imaging and lung function analysis solutions. Founded in 2012 and headquartered in Melbourne, Australia, the company develops and commercializes four-dimensional lung imaging technologies, primarily through its patented XV Technology®. Its core products include the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) that dynamically quantifies ventilation throughout the lungs using X-ray velocimetry; the Computed Tomography-enabled CT LVAS™ that provides functional lung health details via CT scans; the XV Scanner for lung function scanning; and Permetium, a multifunctional imaging system for pulmonary investigations. The company delivers these solutions through a Software-as-a-Service model integrating seamlessly with existing hospital infrastructure, supporting enhanced diagnosis and management of respiratory diseases such as asthma, COPD, interstitial lung disease, and pulmonary fibrosis. Recent major developments include 4DMedical’s strategic acquisition of the U.S.-based medical imaging AI firm Imbio in 2024, which expanded its product portfolio with AI-powered analysis for both lung and cardiothoracic diseases, strengthening its addressable market especially in the United States. In 2025, 4DMedical reported significant revenue growth accompanied by expanded scan volumes and a 24% increase in operational locations globally. The company has entered strategic partnerships, including a key collaboration with Philips to enhance sales and broaden market reach, and secured commercial contracts with Qscan Radiology Clinics in Australia and SMS Biotech in the U.S. for clinical research applications. Its latest innovation, the CT:VQ™ solution, combines ventilation and perfusion analysis to set new benchmarks in cardiothoracic imaging. 4DMedical also recently received FDA Breakthrough Device designation for its IQ-UIP™ software targeting earlier diagnosis of idiopathic pulmonary fibrosis. The company operates primarily in Australia and the United States, serving clinical, research, and pharmaceutical markets, with ongoing expansions in hospital networks and pilot programs to drive adoption. Overall, 4DMedical Limited operates in the healthcare and medical devices industry, focusing on non-invasive, quantitative lung imaging and artificial intelligence-based diagnostic software designed to improve respiratory disease outcomes worldwide.
4DMedical Limited (FDMDF) Discusses Clinical Use of CT:VQ in Patient Selection for Lung Volume Reduction Surgery Transcript
4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and increase Technology Dominance in Software-Based Lung Imaging
4DMedical Limited (FDMDF) Discusses Imaging Technology Portfolio and Market Positioning in Cardio-Pulmonary Diagnostics Transcript
4DMedical Limited (FDMDF) Discusses Expansion of Distribution Agreement for CT:VQ Non-Contrast Lung Imaging Solution Transcript
4DMedical Limited - Special Call
4DMedical's CT:VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology